From the * Department of Epidemiology, Rollins School of Public Health, Emory University; † Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA; Departments of ‡ Preventive Medicine; § Pediatrics (Division of Infectious Diseases); ¶ Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN; ∥ Instituto de Investigación Nutricional, Lima, Peru; and **University of Basel, Basel, Switzerland.
Accepted for publication August 15, 2012.
This study was supported in part by Vanderbilt University, the Vanderbilt CTSA grant UL1 RR024975-01 from National Center for Research Resources /National Institutes of Health and Pfizer (New York, NY; IIR WS1898786[0887X1-4492]). In addition to an institutional grant from Pfizer, KPK has received consulted for Pfizer vaccines, GlaxoSmithKline (Research Triangle Park, NC), Novartis (New York, NY), Sanofi (Bridgewater, NJ) and Merck (Whitehouse Station, NJ), and he has received speaking fees from Pfizer and GlaxoSmithKline. MRG has consulted for Novavax (Rockville, MD); CGG has consulted for GlaxoSmithKline; JVW has consulted for Quidel (Santa Clara, CA) and MedImmune (Gaithersburg, MD).
The authors have no other funding or conflicts of interest to disclose.
Address for correspondence: Keith P. Klugman, MD, PhD, Rollins School of Public Health, 1518 Clifton Road Atlanta, GA 30322. E-mail: [email protected].